Quantitative profiling and identification of differentially expressed plasma proteins in friedreich's ataxia

Journal of Neuroscience Research

Volumn 91, Issue 11, 2013, Pages 1483-1491

  Swarup, Vishnu ^a   Srivastava, Achal K ^a   Padma, Madakasira V ^a   Rajeswari, Moganty R ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Friedreich's ataxia; Neurodegenerative disorder; Protein biomarkers; Proteomics; Triplet repeat expansion

Indexed keywords

ALBUMIN; ALPHA 1 ANTITRYPSIN; ANTIPLASMIN; ANTITHROMBIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN C2; APOLIPOPROTEIN C3; COMPLEMENT COMPONENT C3; FIBRINOGEN; PLASMA PROTEIN; TRANSCRIPTION FACTOR IIIA;

ADOLESCENT; AREFLEXIA; ARTICLE; BABINSKI REFLEX; CLINICAL ARTICLE; CONTROLLED STUDY; DYSARTHRIA; FRIEDREICH ATAXIA; HUMAN; INTERNATIONAL CO OPERATIVE ATAXIA RATING SCALE; LIPID METABOLISM; LIQUID CHROMATOGRAPHY; OXIDATIVE STRESS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEOMICS; RATING SCALE; TANDEM MASS SPECTROMETRY; TWO DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS; WESTERN BLOTTING;

FRIEDREICH'S ATAXIA; NEURODEGENERATIVE DISORDER; PROTEIN BIOMARKERS; PROTEOMICS; TRIPLET REPEAT EXPANSION;

ADOLESCENT; BLOTTING, WESTERN; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; FRIEDREICH ATAXIA; HUMANS; MALE; PROTEOMICS; TANDEM MASS SPECTROMETRY;

EID: 84884729300     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.23262     Document Type: Article

References (49)

1. Adibhatla RM, Hatcher JF. 2008. Phospoholipase A2, reactive oxygen species and lipid peroxidation in CNS pathologies. BMB Rep 41:560-567.
2. Babady NE, Carelle N, Wells RD, Rouault TA, Hirano M, Lynch DR, Delatycki MB, Wilson RB, Isaya G, Puccio H. 2007. Advancements in the pathophysiology of Friedreich's ataxia and new prospects for treatments. Mol Genet Metab 92:23-35.
3. Baggio G, Manzato E, Gabelli C, Fellin R, Martini S, Enzi GB, Verlato F, Baiocchi MR, Sprecher DL, Kashyap ML. 1986. Apolipoprotein C-II deficiency syndrome. Clinical features, lipoprotein characterization, lipase activity, and correction of hypertriglyceridemia after apolipoprotein C-II administration in two affected patients. J Clin Invest 77:520-527.
4. Bencze KZ, Kondapalli KC, Cook JD, McMahon S. 2006. The structure and function of frataxin. Crit Rev Biochem Mol Biol 41:269-291.
5. Boehm T, Scheiber-Mojdehkar B, Kluge B, Goldenberg H, Laccone F, Sturm B. 2011. Variations of frataxin protein levels in normal individuals. Neurol Sci 32:327-330.
6. Brigatti KW, Deutsch EC, Lynch DR, Farmer JM. 2012. Novel diagnostic paradigms for Friedreich ataxia. J Child Neurol 27:1146-1151.
7. Campuzano V, Montermini L, MoltòM D, Pianese L, Cossée M, Cavalcanti F, Monros E, Rodius F, Duclos F, Monticelli A, Zara F, Cañizares J, Koutnikova H, Bidichandani SI, Gellera C, Brice A, Trouillas P, Michele GD, Filla A, Frutos RD, Palau F, Patel PI, Donato SD, Mandel J, Cocozza S, Koenig M, Pandolfo M. 1996. Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 271:1423-1427.
8. Candiano G, Petretto A, Bruschi M, Santucci L, Dimuccio V, Prunotto M, Gusmano R, Urbani A, Ghiggeri GM. 2009. The oxido-redox potential of albumin methodological approach and relevance to human diseases. J Proteomics 73:188-195.
9. Carr ME. 2001. Diabetes mellitus: a hypercoagulable state. J Diab Complic 15:44-54.
10. Cossée M, Schmitt M, Campuzano V, Reutenauer L, Moutou C, Mandel JL, Koenig M. 1997. Evolution of the Friedreich's ataxia trinucleotide repeat expansion: founder effect and premutations. Proc Natl Acad Sci USA. 94:7452-7457.
11. Di Prospero NA, Sumner CJ, Penzak SR, Ravina B, Fischbeck KH, Taylor JP. 2007. Safety, tolerability, and pharmacokinetics of high-dose idebenone in patients with Friedreich ataxia. Arch Neurol 64:803-808.
12. Doupis J, Lyons TE, Wu S, Gnardellis C, Dinh T, Veves A. 2009. Microvascular reactivity and inflammatory cytokines in painful and painless peripheral diabetic neuropathy. J Clin Endocrinol Metab 94:2157-2163.
13. Dziedzic T, Slowik A, Szczudlik A. 2004. Serum albumin level as a predictor of ischemic stroke outcome. Stroke 35:156-158.
14. Erem C, Hacihasanoǧlu A, Celik S, Ovali E, Ersöz HO, Ukinc K, Deger O, Telatar M. 2005. Coagulation and fibrinolysis parameters in type 2 diabetic patients with and without diabetic vascular complications. Med Princ Pract 14:22-30.
15. Frederick WG, Enriquez R, Bookbinder MJ. 1990. Peripheral neuropathy associated with alpha 1-antitrypsin deficiency. Arch Neurol 47:233-235.
16. Freeman WM, Hemby SE. 2004. Proteomics for protein expression profiling in neuroscience. Neurochem Res 29:1065-1081.
17. Friedreich N. 1863. Ueber degenerative Atrophie der spinalen Hinterstrange. Virchows Arch Pathol Anat 26:391-419.
18. Hai T, Wolfgang CD, Marsee DK, Allen AE, Sivaprasad U. 1999. ATF3 and stress responses. Gene Expr 7:321-335.
19. Harada T, Sano M, Matsunaga T. 1992. The effect of anaphylatoxin component on inner ear damage. Acta Otolaryngol 112:265-271.
20. Harding AE. 1984. Hereditary ataxias and related disorders. Edinburgh: Churchill-Livingstone.
21. Haugen AC, Di-Prospero NA, Parker JS, Fannin RD, Chou J, Meyer JN, Halweg C, Collins JB, Durr A, Fischbeck K, Van Houten B. 2010. Altered gene expression and DNA damage in peripheral blood cells from Friedreich's ataxia patients:cellular model of pathology. PLoS Genet 6:e1000812.
22. Heideman M, Norder-Hansson B, Bengtson A, Mollnes TE. 1988. Terminal complement complexes and anaphylatoxins in septic and ischemic patients. Arch Surg 123:188-192.
23. Kario K, Matsuo T, Kobayashi H, Matsuo M, Sakata T, Miyata T. 1995. Activation of tissue factor-induced coagulation and endothelial cell dysfunction in non-insulin-dependent diabetic patients with microalbuminuria. Arterioscler Thromb Vasc Biol 15:1114-1120.
24. Kvasnicka J, Skrha J, Perusicová J, Kvasnicka T, Marková M, Umlaufová A, Pecen L. 1998. Haemostasis, cytoadhesive molecules sE-selectin and sICAM-1 and inflammatory markers in non-insulin dependent diabetes mellitus NIDDM. Sb Lek 99:97-101.
25. Lamont PJ, Davis MB, Wood NW. 1997. Identification and sizing of the GAA trinucleotide repeat expansion of Friedreich's ataxia in 56 patients. Clinical and genetic correlates. Brain 120:673-680.
26. Lindå H, Sköld MK, Ochsmann T. 2011. Activating transcription factor 3, a useful marker for regenerative response after nerve root injury. Front Neurol 2:30.
27. Lolin YI, Ward AM. 1995. Alpha-1-antitrypsin phenotypes and associated disease patterns in neurological patients. Acta Neurol Scand 91:394-398.
28. Luoma PV, Näyhä S, Sikkilä K, Hassi J. 1995. High serum alpha-tocopherol, albumin, selenium and cholesterol, and low mortality from coronary heart disease in northern Finland. J Intern Med 237:49-54.
29. Machalińska A, Dziedziejko V, Mozolewska-Piotrowska K, Karczewicz D, Wiszniewska B, Machaliński B. 2009. Elevated plasma levels of C3a complement compound in the exudative form of age-related macular degeneration. Ophthalmic Res 42:54-59.
30. Mariotti C, Fancellu R, Caldarazzo S, Nanetti L, Di Bella D, Plumari M, Lauria G, Cappellini MD, Duca L, Solari A, Taroni F. 2012. Erythropoietin in Friedreich ataxia: no effect on frataxin in a randomized controlled trial. Mov Disord 27:446-449.
31. Matsushima H, Yoshida H, Machiguchi T, Muso E, Matsuyama E, Tamura T, Sasayama S. 2002. Urinary albumin and TGF β1 levels as renal damage indices in patients with congestive heart failure. Clin Exp Nephrol 6:21-29.
32. Ng DS, O'Connor PW, Mortimer CB, Leiter LA, Connelly PW, Hegele RA. 1996. Case report:retinopathy and neuropathy associated with complete apolipoprotein A-I deficiency. Am J Med Sci 312:30-33.
33. Pandolfo M. 2008. Friedreich's ataxia. Arch Neurol 65:1296-1303.
34. Piemonte F, Pastore A, Tozzi G, Tagliacozzi D, Santorelli FM, Carrozzo R, Casali C, Damiano M, Federici G, Bertini E. 2001. Glutathione in blood of patients with Friedreich's ataxia. Eur J Clin Invest 31:1007-1011.
35. Pineda M, Arpa J, Montero R, Aracil A, Domínguez F, Galván M, Mas A, Martorell L, Sierra C, Brandi N, García-Arumí E, Rissech M, Velasco D, Costa JA, Artuch R. 2008. Idebenone treatment in paediatric and adult patients with Friedreich ataxia:long-term follow-up. Eur J Paediatr Neurol 12:470-475.
36. Rajeswari MR. 2012. DNA triplex structures in neurodegenerative disorder, Friedreich's ataxia. J Biosci 37:519-532.
37. Rizzo G, Tonon C, Valentino ML, Manners D, Fortuna F, Gellera C, Pini A, Ghezzo A, Baruzzi A, Testa C, Malucelli E, Barbiroli B, Carelli V, Lodi, R. 2011. Brain diffusion-weighted imaging in Friedreich's ataxia. Mov Disord 26:705-712.
38. Roche M, Rondeau P, Singh NR, Tarnus E, Bourdon E. 2008. The antioxidant properties of serum albumin. FEBS Lett 582:1783-1787.
39. Schulz JB, Dehmer T, Schöls L, Mende H, Hardt C, Vorgerd M, Bürk K, Matson W, Dichgans J, Beal MF, Bogdanov MB. 2000. Oxidative stress in patients with Friedreich ataxia. Neurol 55:1719-1721.
40. Selak MA, Lyver E, Micklow E, Deutsch EC, Onder O, Selamoglu N, Yager C, Knight S, Carroll M, Daldal F, Dancis A, Lynch DR, Sarry JE. 2011. Blood cells from Friedreich ataxia patients harbor frataxin deficiency without a loss of mitochondrial function. Mitochondrion 11:342-350.
41. Sival DA, Pouwels ME, Van Brederode A, Maurits NM, Verschuuren-Bemelmans CC, Brunt ER, Du Marchie-Sarvaas GJ, Verbeek RJ, Brouwer OF, Van Der HJH. 2011. In children with Friedreich ataxia, muscle and ataxia parameters are associated. Dev Med Child Neurol 53:529-534.
42. Sladkova V, Mareš J, Lubenova B, Zapletalova J, Stejskal D, Hlustik P, Kanovsky P. 2011. Degenerative and inflammatory markers in the cerebrospinal fluid of multiple sclerosis patients with relapsing-remitting course of disease and after clinical isolated syndrome Neurol Res 33:415-420.
43. Soedamah-Muthu SS, Chaturvedi N, Pickup JC, Fuller JH. 2008. EURODIAB Prospective Complications Study Group. Relationship between plasma sialic acid and fibrinogen concentration and incident micro- and macrovascular complications in type 1 diabetes. The EURODIAB Prospective Complications Study PCS. Diabetologia 51:493-501.
44. Swarup V, Srivastava AK, Padma MV, Rajeswari MR. 2011. Quantification of circulating plasma DNA in Friedreich's ataxia and spinocerebellar ataxia types 2 and 12. DNA Cell Biol 30:389-394.
45. Swarup V, Srivastava AK, Rajeswari MR. 2012. Identification and quantification of differentially expressed proteins in plasma of spinocerebellar ataxia type 12. Neurosci Res 73:161-167.
46. Swarup V, Srivastava AK, Padma MV, Moganty RR. 2013. Quantitative profiling and identification of plasma proteins of spinocerebellar ataxia type-2 patients. Neurodegen Dis May 31. [Epub ahead of print].
47. Takabayashi T, Vannier E, Clark BD, Margolis NH, Dinarello CA, Burke JF, Gelfand JA. 1996. A new biologic role for C3a and C3a desArg: regulation of TNF-alpha and IL-1 beta synthesis. J Immunol 156:3455-3460.
48. Tarr PE, Taffé P, Bleiber G, Furrer H, Rotger M, Martinez R, Hirschel B, Battegay M, Weber R, Vernazza P, Bernasconi E, Darioli R, Rickenbach M, Ledergerber B, Telenti A. 2005. Swiss HIV Cohort Study. Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders. J Infect Dis 191:1419-1426.
49. Trouillas P, Takayanagi T, Hallett M, Currier RD, Subramony SH, Wessel K, Bryer A, Diener HC, Massaquoi S, Gomez CM, Coutinho P, Ben Hamida M, Campanella G, Filla A, Schut L, Timann D, Honnorat J, Nighoghossian N, Manyam B. 1997. International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome. The Ataxia Neuropharmacology Committee of the World Federation of Neurology. J Neurol Sci 145:205-211.